• STAT Diagnostica was founded in 2010 and focuses on the development of Point of Care diagnostic solutions for clinical applications.
• The transaction is the sixth investment managed by Ysios Capital Partners, the third in Spain and the first in diagnostics.
• The proceeds of this round will fund the initial development of STAT Diagnostica‘s Point of Care diagnostics solution and the hiring of the appropriate team.

Barcelona 15th June 2011 – Ysios Capital Partners today announces that it has led a €2M Series A investment in STAT Diagnostica, a company based in the Barcelona Science Park. The venture fund from Instituto de Crédito Oficial (ICO) FESpyme FCR, managed by Axis Participaciones Empresariales, has joined the round.

STAT Diagnostica was founded in 2010, and is focused on the development of Point of Care solutions for clinical diagnostics with the objective of simplifying current procedures and reducing time to result.

Proceeds from Series A will allow STAT Diagnostica to develop its in-vitro Point of Care diagnostics platform. This is a versatile, easy to use solution that can perform both molecular diagnostics and immunoassay. Its main applications will be in the fields of infectious diseases, antibiotic resistances and measuring biomarkers in critical patients or urgent situations.

STAT Diagnostica’s platform will enable multi analyte and multi sample detection as well as a significant reduction of time to result, in some cases from several days to one hour or even 15 minutes. This will help physicians to quickly determine appropriate treatments for the patients and it will have direct and indirect positive impact in cost for the health systems.

“The platform that we are developing will allow us to perform diagnostic tests close to the patient and to obtain results in a short period of time without the need to involve central laboratories. In addition, the simplicity of use, reliability and capacity to generate complementary analytical results, will be key to help the physician to determine appropriate treatments from the very beginning in patients at risk”, says Jordi Carrera, Managing Director and Co-Founder of STAT Diagnostica.

“STAT Diagnostica fits very well with our investment strategy. It is addressed to a medical need currently not properly solved and its implementation will represent a benefit for the patient and important savings for the health systems. It is expected that Point of Care diagnostics market will grow significantly in the coming years, and STAT’s platform gathers a number of competitive advantages over products in the market and in development. The product profile and the experience and commitment of the founders, convinced us to invest in STAT Diagnostica”, says Raúl Martín-Ruiz, Investment Director of Ysios Capital Partners.

Note

About Ysios Capital Partners

Ysios Capital Partners is an independent venture capital firm in Spain providing private equity financing to early and mid-stage human healthcare and biotechnology companies with special focus on pharmaceuticals, diagnostics and medical devices. Ysios launched its first fund, Ysios BioFund I, of € 69 million in 2008.

Ysios has a team of eight professionals with diverse backgrounds in life sciences and healthcare, venture capital, managing start-ups, and corporate finance. Ysios’ Partners are Joël Jean-Mairet, ex CEO of GLYCART Biotechnoloy AG; Julia Salaverria, ex Director of Funds in Talde and Josep Lluís Sanfeliu, ex Corporate Finance Business Development Manager at Almirall.

With this investment, Ysios has invested in a total of 6 companies through its first fund Ysios BioFund I: Cellerix (Cell therapy–Madrid) – recently merged with Tigenix-, EndoSense (Medical devices–Geneva), BioVex (Oncology–Boston)-successfully sold to AMGEN-, Cardoz (Cardiology- Stockholm), Sabirmedical (Medical Devices-Barcelona) and STAT Diagnostica (Diagnostics-Barcelona)

About Axis

Axis Participaciones Empresariales is one of the oldest players in Private Equity in Spain. It was founded in 1986 in order to foster venture capital in Spain. They have invested more than €250M in over 130 companies.

ysiosdev

See Full Bio